Evidence map›Paper›PMID 36974067›Full record

ArticleFrontiers in medicine2023

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes.

Alexander Egeberg, Joseph F Merola, Knut Schäkel, Luis Puig, Patrick D Mahar, Isabella Yali Wang, Imre Pavo, Christopher Schuster, Christopher E M Griffiths

Open access · goldFull text readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 7 countries.

Alexander EgebergBispebjerg and Frederiksberg Hospital, Copenhagen University, Copenhagen, Denmark.
Joseph F MerolaDivision of Rheumatology, Department of Dermatology and Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States.
Knut SchäkelDepartment of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
Luis PuigDermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Patrick D MaharEli Lilly and Company, Indianapolis, IN, United States.
Isabella Yali WangEli Lilly and Company, Indianapolis, IN, United States.
Imre PavoEli Lilly and Company, Indianapolis, IN, United States.
Christopher SchusterEli Lilly and Company, Indianapolis, IN, United States.
Christopher E M GriffithsDermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom.
Eli Lilly (United States) · USFrederiksberg Hospital · DKHarvard University · USHospital de Sant Pau · ESMedical University of Vienna · ATRoyal Children's Hospital · AUSalford Royal Hospital · GBUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fmed.2022.1092688.].

Indexed as

ixekizumabmoderate-to-severe psoriasisobesityprediabetestype 2 diabetes

Identifiers

PMID36974067
PMCPMC10038792
OpenAlexW4323834800

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.